Titlebook: endoCANNABINOIDS; Actions at Non-CB1/C Mary E. Abood,Roger G Sorensen,Nephi Stella Book 2013 Springer Science+Business Media New York 2013

Hemiplegia

Allege

GPR55 in the CNSme of the non-CB./CB./TRPV1 effects of cannabinoid compounds. However, it rapidly became clear that the pharmacology and signaling of GPR55 were quite complicated. Work over the last few years has found that lysophosphatidyl inositol is a major endogenous ligand for GPR55, with phytocannabinoids and

linguistics

The Role of GPR55 in Bone Biologyaims to summarise the work that became the first study to demonstrate a non-neuronal physiological role for GPR55 in vivo. In summary, male mice lacking GPR55 develop a high bone mass phenotype due to impairment in osteoclast function—consistent with GPR55 agonists O-1602 and LPI stimulating osteocl

ALTER

The Role of GPR55 in Cancervior. As will be described in this chapter, this receptor has been directly or indirectly related to the basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and metastatic capability. GPR55 activation promotes cell proliferation, produces pr

choroid

發(fā)源

Cantankerous

ablate

Hdl348

過于平凡

Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addictionome proliferator-activated alpha nuclear receptor (PPARα), which regulates genes involved in lipid metabolism and inflammatory responses, is a viable target for treating nicotine dependence. The endogenous ligands for PPARα, oleoylethanolamide and palmitoylethanolamide, are structurally similar to a